Published in Blood on January 01, 1999
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A (2007) 2.11
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev (2013) 1.68
Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med (2011) 1.61
Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene (2004) 1.57
Arsenic trioxide - An old drug rediscovered. Blood Rev (2010) 1.49
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther (2009) 1.27
BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood (2008) 1.27
Pink-eyed dilution protein modulates arsenic sensitivity and intracellular glutathione metabolism. Mol Biol Cell (2002) 1.14
Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia (2008) 1.13
Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells. J Biochem Mol Toxicol (2008) 1.11
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs (2006) 1.06
Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther (2011) 1.04
Pathways of arsenic uptake and efflux. Curr Top Membr (2012) 1.02
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther (2009) 0.98
Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem (2009) 0.95
Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis (2011) 0.95
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol (2010) 0.94
β-Elemene piperazine derivatives induce apoptosis in human leukemia cells through downregulation of c-FLIP and generation of ROS. PLoS One (2011) 0.93
Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood (2005) 0.91
The sensitivity of digestive tract tumor cells to As2O3 is associated with the inherent cellular level of reactive oxygen species. World J Gastroenterol (2002) 0.91
Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother Pharmacol (2008) 0.91
Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia (2012) 0.91
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol (2009) 0.90
Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. J Virol (2008) 0.89
A combination of two antioxidants (an SOD mimic and ascorbate) produces a pro-oxidative effect forcing Escherichia coli to adapt via induction of oxyR regulon. Anticancer Agents Med Chem (2011) 0.89
Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome. Proc Natl Acad Sci U S A (2004) 0.88
Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res (2012) 0.86
The effects of high concentrations of vitamin C on cancer cells. Nutrients (2013) 0.85
Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia. Arch Drug Inf (2009) 0.84
Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo. J Virol (2013) 0.84
Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World J Gastroenterol (2005) 0.83
Arsenic trioxide and neuroblastoma cytotoxicity. J Bioenerg Biomembr (2007) 0.83
Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes. Inorg Chem (2013) 0.82
A review of arsenic trioxide and acute promyelocytic leukemia. Int J Hematol Oncol Stem Cell Res (2014) 0.81
Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1. Mol Pharmacol (2010) 0.80
Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma. PLoS One (2013) 0.80
Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. Br J Haematol (2010) 0.79
Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model. Clin Exp Med (2013) 0.79
Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats. World J Gastroenterol (2005) 0.79
Tetraarsenic Hexoxide Induces Beclin-1-Induced Autophagic Cell Death as well as Caspase-Dependent Apoptosis in U937 Human Leukemic Cells. Evid Based Complement Alternat Med (2011) 0.79
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells. Leuk Lymphoma (2010) 0.79
Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways. Biomed Res Int (2013) 0.78
The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. World J Surg Oncol (2010) 0.78
Involvement of glutathione as a mechanism of indirect protection against spontaneous ex vivo apoptosis associated with bovine leukemia virus. J Virol (2004) 0.78
Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface. Mol Cancer (2014) 0.77
Preparation of a nanosized as(2)o(3)/mn(0.5)zn(0.5)fe(2)o(4) complex and its anti-tumor effect on hepatocellular carcinoma cells. Sensors (Basel) (2009) 0.76
Physiologic Doses of Ascorbic Acid Increase Arsenic Trioxide Toxicity in Human Jurkat -T Lymphoma Cells. Met Ions Biol Med (2015) 0.75
Comparison of As(2)O(3) and As(4)O(6) in the detection of SiHa cervical cancer cell growth inhibition pathway. Cancer Res Treat (2004) 0.75
ASCORBIC ACID - MODULATION OF ARSENIC TRIOXIDE TOXICITY: IMPLICATION FOR THE CLINICAL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA. Met Ions Biol Med (2015) 0.75
Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells. PLoS One (2014) 0.75
Tetraarsenic oxide-mediated apoptosis in a cervical cancer cell line, SiHa. Cancer Res Treat (2005) 0.75
A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. Cell Metab (2017) 0.75
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst (1998) 2.75
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst (1999) 2.41
Genetic diversity among sapoviruses. Arch Virol (2004) 2.33
Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood (1999) 2.26
Deranged DNA synthesis by bone marrow from vitamin B-12-deficient humans. Br J Haematol (1968) 1.93
Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol (1994) 1.86
Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Proc Natl Acad Sci U S A (1996) 1.86
Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. J Biol Chem (1997) 1.85
Transatrial access to the normal pericardial space: a novel approach for diagnostic sampling, pericardiocentesis, and therapeutic interventions. Circulation (1998) 1.74
Cellular retinol-binding protein expression and breast cancer. J Natl Cancer Inst (2000) 1.68
Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol (1994) 1.65
Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene (2001) 1.59
Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene (1999) 1.58
PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A (1994) 1.57
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. Eur Rev Med Pharmacol Sci (2015) 1.50
Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leuk Res (2001) 1.46
Stenting for in-stent restenosis: A long-term clinical follow-up. Catheter Cardiovasc Interv (1999) 1.43
Determination of blood flow and endothelial shear stress in human coronary artery in vivo. J Invasive Cardiol (1999) 1.41
Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood (1995) 1.39
Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood (2000) 1.38
The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol (1998) 1.38
Clinical studies of hemodialysis access through formaldehyde-fixed arterial allografts. Kidney Int (2007) 1.38
Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sci U S A (1997) 1.36
Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest (1993) 1.36
Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain. Proc Natl Acad Sci U S A (1995) 1.33
Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem (1999) 1.30
Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia. Oncogene (1996) 1.28
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood (2001) 1.27
RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene (2009) 1.27
Myasthenia gravis, chronic lymphocytic leukemia, and autoimmune hemolytic anemia. "A spectrum of thymic abnormalities? Arch Intern Med (1967) 1.24
Radioisotopic assay for measurement of serum folate levels. Blood (1971) 1.24
Body Shape Questionnaire: studies of validity and reliability. Int J Eat Disord (1996) 1.24
Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration. Equine Vet J (2002) 1.24
Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest (1988) 1.24
RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc Natl Acad Sci U S A (1996) 1.23
Release of vitamin B12--binding protein by human leukocytes in vitro. J Clin Invest (1970) 1.22
Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J Nucl Med (1990) 1.22
Ongoing activity in peripheral nerve: injury discharge. Exp Neurol (1974) 1.21
Measurement of red cell folate levels by 3H-pteroylglutamic acid (3H-PteGlu) radioassay. Br J Haematol (1974) 1.20
Solution-state structure of a DNA dodecamer duplex containing a Cis-syn thymine cyclobutane dimer, the major UV photoproduct of DNA. J Mol Biol (1998) 1.18
Isolation and characterization of a novel vitamin B12-binding protein associated with hepatocellular carcinoma. J Clin Invest (1975) 1.15
Cloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon-stimulated genes. Proc Natl Acad Sci U S A (1997) 1.14
Second generation knockout sickle mice: the effect of HbF. Blood (2001) 1.14
A tumor-related vitamin B12 binding protein in adolescent hepatoma. N Engl J Med (1973) 1.12
Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia (2004) 1.10
Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci U S A (1999) 1.10
Measurement of serum folate levels and serum folic acid-binding protein by 3H-PGA radioassay. Blood (1973) 1.10
Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. Leukemia (1994) 1.08
Mechanism of triamterene-induced megaloblastosis. Ann Intern Med (1970) 1.07
Occurrence of distinct PML-RAR-alpha fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogene (1992) 1.06
Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res (1997) 1.06
Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia (1993) 1.05
Role of folate binding proteins in folate metabolism. Lab Invest (1989) 1.05
Antineoplastic agents. III: Steroidal glycosides from Solanum nigrum. Planta Med (1999) 1.03
Axon outgrowth is regulated by an intracellular purine-sensitive mechanism in retinal ganglion cells. J Biol Chem (1998) 1.02
Mechanism of pyrimethamine-induced megaloblastosis in human bone marrow. N Engl J Med (1969) 1.02
Appearance of C-type virus-like particles after co-cultivation of a human tumor-cell line with rat (XC) cells. Int J Cancer (1975) 1.02
The cellular retinoic acid binding protein II is a positive regulator of retinoic acid signaling in breast cancer cells. Cancer Res (1997) 1.01
Cryoprotected Lactobacillus casei: an approach to standardization of microbiological assay of folic acid in serum. Clin Chem (1981) 1.00
Stripping of Descemet's membrane associated with intraocular lens implantation. Arch Ophthalmol (1983) 1.00
Inhibition of mouse GATA-1 function by the glucocorticoid receptor: possible mechanism of steroid inhibition of erythroleukemia cell differentiation. Mol Endocrinol (1993) 0.99
Switch from fetal to adult hemoglobin is associated with a change in progenitor cell population. J Clin Invest (1983) 0.99
Bilateral cytomegalovirus panuveitis after high-dose corticosteroid therapy. Am J Ophthalmol (1979) 0.99
Toxoplasmic scleritis. Ophthalmology (1988) 0.98
Urgent coronary bypass surgery for failed percutaneous coronary intervention in the stent era: Is backup still necessary? Am Heart J (2001) 0.98
Effect of association, dissociation and positive self-talk strategies on endurance performance. Can J Appl Sport Sci (1984) 0.97
Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res (1983) 0.97
Primary angioleiomyoma in the sellar region: a case report and literature review. Clin Neuropathol (2009) 0.96
Effect of retinoic acid isomers on proliferation, differentiation and PML relocalization in the APL cell line NB4. Leukemia (1995) 0.96
Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia (2005) 0.95
Nocardial endophthalmitis: report of two cases studied histopathologically. Br J Ophthalmol (1988) 0.95
Characteristics of folic acid-binding protein in folate-deficient serum. Blood (1973) 0.95
Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene. Proc Natl Acad Sci U S A (1999) 0.95
Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. Oncogene (2006) 0.94
Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. Leuk Res (1999) 0.94
Absorption and malabsorption of vitamin B 12. Am J Med (1970) 0.92
Cell cycle gene expression and E2F transcription factor complexes in human melanoma cells induced to terminally differentiate. Oncogene (1995) 0.92
Age-related changes in polyamines in memory-associated brain structures in rats. Neuroscience (2008) 0.91
The isolation and characterization of the folate binding protein from goat milk. FEBS Lett (1977) 0.91
The purification and characterization of the low molecular weight human folate binding protein using affinity chromatography. Biochemistry (1975) 0.91
Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia (2012) 0.91
A purine-sensitive pathway regulates multiple genes involved in axon regeneration in goldfish retinal ganglion cells. J Neurosci (2000) 0.90
Erythropoiesis in Fanconi's anemia. Blood (1991) 0.89
mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development. Oncogene (2012) 0.89
A novel way to statistically analyze morphologic changes in Dmp1-null osteocytes. Connect Tissue Res (2014) 0.89
Elevation of intraocular pressure after pars plana vitrectomy. Albrecht Von Graefes Arch Klin Exp Ophthalmol (1976) 0.88
Uptake of tritiated folates by human bone marrow cells in vitro. Br J Haematol (1971) 0.88
Effect of intracellular folate concentration on the modulation of 5-fluorouracil cytotoxicity by the elevation of phosphoribosylpyrophosphate in cultured human KB cells. Cancer Res (1987) 0.88
Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells. J Cell Physiol (2000) 0.87
Evidence for a clonal model for hemoglobin switching. Prog Clin Biol Res (1983) 0.87
Folate binding proteins. Br J Haematol (1975) 0.87
Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. Leukemia (2006) 0.86
The design of selective and non-selective combination therapy for acute promyelocytic leukemia. Curr Top Microbiol Immunol (2007) 0.86